Roche Holding AG Basel American Depositary Shares (OP:RHHBY)

52.13 -0.12 (-0.23%)

Delayed Quote Updated: 10:53 AM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Roche Holding AG Basel American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

38 39 Next >

IEFA vs. VXUS: Both Are Cheap. Both Are Broad. Here Is the Key Difference Long-Term Investors Need to Understand. ↗

July 02, 2026

These international stock ETFs from iShares and Vanguard are very different once you look under the surface.

Via The Motley Fool

Topics ETFs

Wall Street Thinks This Biotech Stock Can Soar 45%. Here's Why Analysts Are Right. ↗

July 02, 2026

Analysts have given Alnylam Pharmaceuticals an average price target of $436.

Via The Motley Fool

Genentech’s Divarasib Shows Superiority in Head-to-Head Phase III Trial Against Approved KRAS G12C Inhibitors in Non-Small Cell Lung Cancer

July 02, 2026

From Genentech

Via Business Wire

FDA Grants Priority Review To Genentech’s Application for Enspryng, the First and Only At-Home Subcutaneous Treatment Option for Thyroid Eye Disease (TED)

June 30, 2026

From Genentech

Via Business Wire

Will SpaceX Stock Double Anytime Soon? No -- but These 3 Stocks Could ↗

June 29, 2026

These stocks are better bets to skyrocket than the much-hyped rocket stock.

Via The Motley Fool

Jazz Pharmaceuticals' Lung Cancer Drug Setback in Late-Stage Trials: Here's Why the Stock Impact May Be More Limited Than It Looks ↗

June 23, 2026

The long-term thesis remains largely unchanged.

Via The Motley Fool

MissionIRNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Advances Novel Multiple Sclerosis Therapy Toward Phase 2 Trials

June 22, 2026

Via Investor Brand Network

Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis

June 22, 2026

Via Investor Brand Network

Teva Just Delivered More Good News on Its Biggest Growth Driver. Is the Stock Still a Bargain? ↗

June 19, 2026

Teva has been building its comeback, and the latest studies on Austedo and Austedo XR will help further that momentum.

Via The Motley Fool

FDA Accepts Supplemental Biologics License Application for Genentech’s Lunsumio and Polivy Combination for People With Relapsed or Refractory Large B-Cell Lymphoma

June 18, 2026

From Genentech

Via Business Wire

Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis

June 22, 2026

From BioMedWire

Via GlobeNewswire

FDA Grants Priority Review for Genentech’s Tecentriq for a Certain Type of Stage III Colon Cancer

June 11, 2026

From Genentech

Via Business Wire

IXUS vs. IEFA: Which International ETF Is Better for Most Investors? ↗

June 10, 2026

When buying international ETFs, owning more stocks in more countries might be a better bet.

Via The Motley Fool

Topics ETFs

FDA Accepts New Drug Application for Genentech’s Giredestrant in ER-Positive Early-Stage Breast Cancer, the First and Only Oral SERD With Positive Phase III Results in the Curative Setting

June 02, 2026

From Genentech

Via Business Wire

Genentech to Present New Data Advancing Its Obesity Portfolio at the American Diabetes Association’s 2026 Scientific Sessions

June 01, 2026

From Genentech

Via Business Wire

President Trump's Drug Pricing Policies Could Hurt Drugmakers' Profits. Time to Sell Pharma Stocks? ↗

May 26, 2026

Don't be too quick to give up on the industry.

Via The Motley Fool

Topics Economy Government

Recursion Pharmaceuticals Just Hit a 52-Week Low. Is This Former Nvidia Holding a Smart Buy Now? ↗

May 25, 2026

The stock looks cheap, but appearances can be deceiving.

Via The Motley Fool

Topics Artificial Intelligence

Genentech to Present New Data at ASCO 2026, Reinforcing Giredestrant's Potential to Transform the Treatment Paradigm in Early Breast Cancer

May 19, 2026

From Genentech

Via Business Wire

3 International ETFs for Investors Looking Beyond U.S. Stocks ↗

May 18, 2026

These three international ETFs offer diversification and surprisingly strong dividends -- with the same low expense ratio of 0.07%.

Via The Motley Fool

Topics Artificial Intelligence ETFs

Eli Lilly Stock: Next Stop $2,000? ↗

May 18, 2026

The company is riding an incredible tailwind.

Via The Motley Fool

Genentech to Present Extensive Data Showcasing Its Industry-Leading Ophthalmology Portfolio at ARVO 2026

April 30, 2026

From Genentech

Via Business Wire

Genentech Partners With Comedy Icon Damon Wayans and diaTribe to Address Diabetes-Related Vision Loss With ‘All Eyes on DME’ Campaign

April 24, 2026

From Genentech

Via Business Wire

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Leads Shift Toward Pipeline-Driven Valuation in Biotech Sector

April 22, 2026

Via Investor Brand Network

Topics Intellectual Property

Genentech’s Fenebrutinib Significantly Reduced Relapses Versus Standard of Care to Approximately One Every 17 Years in RMS

April 21, 2026

From Genentech

Via Business Wire

Advancing Drug Pipelines Drive Biotech Valuations as Scientific Progress Gains Financial Recognition

April 22, 2026

From BioMedWire

Via GlobeNewswire

Genentech’s Enspryng (Satralizumab) Reduces Risk of Relapses by 68% Demonstrating Potential to Become First Treatment for MOGAD

April 21, 2026

From Genentech

Via Business Wire

FDA Accepts Application for Genentech’s Gazyva for the Treatment of the Most Common Form of Lupus

April 21, 2026

From Genentech

Via Business Wire

Could AbbVie Crash Lilly's Weight‑Loss Party? ↗

April 14, 2026

AbbVie is making progress in this market, but it is still far behind the leader.

Via The Motley Fool

The Science of Scale: An In-Depth Look at Regeneron Pharmaceuticals (REGN) in 2026

April 13, 2026

As of today, April 13, 2026, Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) stands as a titan of the biotechnology sector, representing a rare blend of scientific purity and commercial dominance. In an...

Via Finterra

Topics Earnings Economy Intellectual Property

C4 Therapeutics Expands Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates (DACs)

April 09, 2026

From C4 Therapeutics, Inc.

Via GlobeNewswire

< Previous 1 2 3 4 5 6 7 8 9

...

38 39 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.